2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, JH T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & Lymphoma 2021, 63: 821-833. PMID: 34865586, DOI: 10.1080/10428194.2021.2010057.Peer-Reviewed Original ResearchConceptsFollicular lymphomaTumor regressionAnti-tumor immune responseToll-like receptor 4 agonistAbscopal tumor regressionAdverse events gradeImmune-mediated responsePhase 1/2 trialOverall response rateEarly phase studiesLow-dose radiationDose expansionDose escalationPreliminary efficacyTLR4 agonistImmune responseUnexpected toxicitiesEvents gradeIntratumoral injectionResponse ratePatientsLymphomaPembrolizumabAgonistsInjectionIncidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infection
2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib
2011
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
Saif MW, Isufi I, Peccerillo J, Syrigos KN. Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma. Gastroenterology Research And Practice 2011, 2011: 616080. PMID: 21687621, PMCID: PMC3113260, DOI: 10.1155/2011/616080.Peer-Reviewed Original ResearchHepatocellular carcinomaCerebrovascular accidentVenous thrombotic eventsNormal systolic functionCases of patientsHead CT scanPrompt discontinuationAcute abnormalitiesCerebrovascular eventsNeurologic symptomsSystolic functionThrombotic eventsSecond patientCarotid ultrasoundSignificant stenosisRisk factorsMultikinase inhibitorCT scanLeft ventriclePatientsSorafenibAngiogenetic agentsHeart chambersCarcinomaLaboratory data
2010
Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13
Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology 2010, 50: 824-829. PMID: 21149242, DOI: 10.1093/rheumatology/keq395.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraMicroangiopathic haemolytic anaemiaThrombocytopenic purpuraHaemolytic anaemiaOutcome of TTPTreatment of TTPIdiopathic thrombotic thrombocytopenic purpuraWorse overall prognosisSystemic lupus erythematosusRole of ADAMTS13Inactive lupusFatal complicationOverall prognosisLupus erythematosusUncommon formSLEADAMTS13PurpuraSimilar improvementsAnemiaCurrent understandingErythematosusComplicationsPatientsLupusRole of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDeoxycytidineDose-Response Relationship, DrugEpirubicinFemaleFluorouracilGamma-Aminobutyric AcidGastrointestinal NeoplasmsGemcitabineHumansMaleMiddle AgedNeurotoxicity SyndromesOrganoplatinum CompoundsOxaliplatinPregabalinConceptsSensory neuropathyTarget doseLow dosesDose-related side effectsEfficacy of pregabalinOxaliplatin-induced neurotoxicityRole of pregabalinMajority of patientsGastrointestinal cancer patientsOnset of benefitGastrointestinal malignanciesHead trialsNeurological symptomsOxaliplatin useCancer patientsSide effectsPregabalinGrade 2PatientsNeuropathyNeurotoxicityDoseDosesEfficacyTreatment